Post hoc exploratory analysis of DUPLEX in patients with genetic FSGS (31 podocyte variants, 25 COL4A3-5, 14 APOL1 high-risk): sparsentan reduced proteinuria with numerically more complete remission than irbesartan, and fewer reached the composite kidney endpoint.
Secondary analysis
Yee et al. Antiproteinuric Effect of Sparsentan in Patients with Genetic-Associated FSGS Enrolled in the DUPLEX Trial